These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

999 related items for PubMed ID: 18371137

  • 1. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C.
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [Abstract] [Full Text] [Related]

  • 2. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT.
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR.
    Arzneimittelforschung; 2010 Dec; 60(6a):386-98. PubMed ID: 20648930
    [Abstract] [Full Text] [Related]

  • 4. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F, Löhr B, Laubender RP, Tillack C, Schnitzler F, Breiteneicher S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.
    Digestion; 2012 Dec; 85(1):47-54. PubMed ID: 22179489
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P, Rumyantsev V.
    Arzneimittelforschung; 2010 Dec; 60(6a):373-85. PubMed ID: 20648929
    [Abstract] [Full Text] [Related]

  • 6. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A.
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
    [Abstract] [Full Text] [Related]

  • 7. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J.
    Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
    [Abstract] [Full Text] [Related]

  • 8. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.
    Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R.
    Am J Obstet Gynecol; 2008 Oct; 199(4):435.e1-7. PubMed ID: 18928998
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010 Oct; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 10. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, Barish C, Bhaskar BS, Smith-Nguyen GN, Butcher A, Koch TA, Goodnough LT.
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [Abstract] [Full Text] [Related]

  • 11. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group.
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
    Iqbal T, Stein J, Sharma N, Kulnigg-Dabsch S, Vel S, Gasche C.
    Dig Dis Sci; 2015 May; 60(5):1375-81. PubMed ID: 25501922
    [Abstract] [Full Text] [Related]

  • 13. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy.
    Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, Ball MJ, Seaton D, Brain T, Rasko JE.
    J Intern Med; 2010 Sep; 268(3):286-95. PubMed ID: 20546462
    [Abstract] [Full Text] [Related]

  • 14. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators.
    N Engl J Med; 2009 Dec 17; 361(25):2436-48. PubMed ID: 19920054
    [Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J, Aksan A, Klemm W, Nip K, Weber-Mangal S, Dignass A.
    J Crohns Colitis; 2018 Jun 28; 12(7):826-834. PubMed ID: 29955835
    [Abstract] [Full Text] [Related]

  • 16. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O, Richard-Davis G, Morris T, Armstrong J.
    Clin Ther; 2007 Aug 28; 29(8):1682-91. PubMed ID: 17919549
    [Abstract] [Full Text] [Related]

  • 17. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Aug 28; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 18. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
    Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE.
    Nephrol Dial Transplant; 2010 Jul 28; 25(7):2368-75. PubMed ID: 20466657
    [Abstract] [Full Text] [Related]

  • 19. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP, Kent AB, Kerr PG, Healy H, Irish AB, Cooper B, Kark A, Roger SD.
    Nephrol Dial Transplant; 2010 Mar 28; 25(3):920-6. PubMed ID: 19906658
    [Abstract] [Full Text] [Related]

  • 20. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
    Befrits R, Wikman O, Blomquist L, Hjortswang H, Hammarlund P, Bajor A, Klintman D, Blom H.
    Scand J Gastroenterol; 2013 Sep 28; 48(9):1027-32. PubMed ID: 23889159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.